12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday’s after-market session. The market value of their…
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic
Trevi Therapeutics Gears Up for Data-Rich Year with Haduvio Clinical Trials
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell
• Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Trevi Therapeutics’s Earnings: A Preview
Trevi Therapeutics (NASDAQ:TRVI) is set to give its latest quarterly earnings report on Thursday, 2023-11-09. Here’s what investors…
Trevi Therapeutics Announces Results From Phase 2b/3 PRISM Open-Label Extension Study Of Haduvio In Prurigo Nodularis
Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatmentSafety data over 52 weeks: treatment was well tolerated and consistent with 14-week blinded safety
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell
• IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares moved upwards by 92.0% to $4.78 during Tuesday’s pre-market session. The market value…
Trevi Therapeutics Announces Publication Of Data From The CANAL Trial In IPF Chronic Cough In NEJM Evidence
Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related coughThe mean change in 24-hour objective cough frequency was similar in patients with